In 2006, a clinical trial for a new drug intended to treat leukemia and autoimmune diseases turned into a medical catastrophe. Eight healthy volunteers were administered the drug, TGN1412, only to suffer from a severe, systemic inflammatory response that left them in critical condition. As the volunteers fought for their lives in intensive care, the incident sparked a massive investigation into the safety protocols and potential for human error in pharmaceutical testing, forever changing the landscape of medical research in Europe.